Lloberas J, Muoz JP, Hernndez-lvarez MI, Cardona PJ, Zorzano A, Celada A
The RR for the occurrence of respiratory disease in patients receiving Albiglutide was 0.93 (95% CI 0.791.10, p = 0.40) compared to other interventions
You can also contact our support team who will do this for you
TSND-201 for the Treatment of PTSDNeuroplastogen TSND-201 for the Treatment of PTSD Blake Mandell Blake Mandell 8moBlake Mandell shared thisWe're hiring for an Associate Director, Clinical Operations and a Director of Clinical Development (MD required)
Lab Invest 2000
Jalleh RJ, Plummer MP, Marathe CS, Umapathysivam MM, Quast DR, Rayner CK, Jones KL, Wu T, Horowitz M, Nauck MA (2024) Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide